Psoriasis is associated with increased risk of cardiovascular disease, but its effect on the course of cardiovascular disease remains unknown. The study show patients with hypertension and psoriasis more often required cardiovascular procedures and surgeries than hypertensive patients without psoriasis. The study was published in the Journal of Dermatology.

The results suggest that hypertensive patients withconcurrent psoriasis experience an earlier and more aggressive disease progression of hypertension, compared with general hypertensive patients.

Hypertension & Psoriasis

Our study will show that patients with hypertension and psoriasis will likely require more intensive assessment for cardiovascular interventions and a more aggressive hypertensive regimen to achieve adequate control.

Psoriasis increases the incidence of hypertension and cardiovascular disease. However, its effect on the course of cardiovascular disease remains unknown. To investigate whether patients with psoriasis and hypertension have a higher requirement for cardiovascular treatment and surgery with hypertension but without psoriasis, we used the Taiwan National Health Insurance Research Database to identify patients with new onset hypertension during 2005-2006.

Among those patients, those with psoriasis ( n  = 4039) were matched in a 1: 1 ratio by age and sex with patients without psoriasis . The association between psoriasis and cardiovascular interventions was examined using time-varying Cox proportional hazards models.

Psoriasis was associated with an increased risk for cardiovascular procedure and surgery in patients with hypertension (adjusted hazard ratio [aHR], 1.28; 95% confidence interval [CI], 1.07–1.53). When no psoriasis served as a reference group, the aHRs were higher for women than for men, and for patients aged 50–64 years than for younger and older patients.

Severe Psoriasis

Patients with severe psoriasis or psoriatic arthritis tended to have higher risks of cardiovascular procedure and surgery than patients with mild psoriasis (aHR, 1.22; 95% CI, 0.98–1.51) or patients without psoriatic arthritis (aHR, 1.15; 95% CI, 0.84–1.58), respectively, did, although not reaching statistical significance.

Patients with hypertension and psoriasis had a greater requirement for cardiovascular interventions than hypertensive patients without psoriasis. More intense assessments for cardiovascular interventions may be necessary for patients with concurrent hypertension and psoriasis than general hypertension patients.